Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma

被引:76
作者
Sun, Matthew Z. [1 ]
Oh, Taemin [2 ]
Ivan, Michael E. [1 ]
Clark, Aaron J. [1 ]
Safaee, Michael [1 ]
Sayegh, Eli T. [2 ]
Kaur, Gurvinder [2 ]
Parsa, Andrew T. [2 ]
Bloch, Orin [2 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA
[2] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
glioblastoma; overall survival; progression-free survival; treatment delay; The Cancer Genome Atlas; oncology; ADJUVANT TEMOZOLOMIDE; WAITING-TIMES; RADIOTHERAPY; DELAY; CONCOMITANT; RADIATION; EORTC;
D O I
10.3171/2014.9.JNS14193
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECT There are few and conflicting reports on the effects of delayed initiation of chemoradiotherapy on the survival of patients with glioblastoma. The standard of care for newly diagnosed glioblastoma is concurrent radiotherapy and temozolomide chemotherapy after maximal safe resection; however, the optimal timing of such therapy is poorly defined. Given the lack of consensus in the literature, the authors performed a retrospective analysis of The Cancer Genome Atlas (TCGA) database to investigate the effect of time from surgery to initiation of therapy on survival in newly diagnosed glioblastoma. METHODS Patients with primary glioblastoma diagnosed since 2005 and treated according to the standard of care were identified from TCGA database. Kaplan-Meier and multivariate Cox regression analyses were used to compare overall survival (OS) and progression-free survival (PFS) between groups stratified by postoperative delay to initiation of radiation treatment. RESULTS There were 218 patients with newly diagnosed glioblastoma with known time to initiation of radiotherapy identified in the database. The median duration until therapy was 27 days. Delay to radiotherapy longer than the median was not associated with worse PFS (HR = 0.918, p = 0.680) or OS (HR = 1.135, p = 0.595) in multivariate analysis when controlling for age, sex, KPS score, and adjuvant chemotherapy. Patients in the highest and lowest quartiles for delay to therapy (<= 20 days vs >= 36 days) did not statistically differ in PFS (p = 0.667) or OS (p = 0.124). The small subset of patients with particularly long delays (>42 days) demonstrated worse OS (HR = 1.835, p = 0.019), but not PFS (p = 0.74). CONCLUSIONS Modest delay in initiation of postoperative chemotherapy and radiation does not appear to be associated with worse PFS or OS in patients with newly diagnosed glioblastoma, while significant delay longer than 6 weeks may be associated with worse OS.
引用
收藏
页码:1144 / 1150
页数:7
相关论文
共 50 条
  • [21] An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825
    Gittleman, Haley
    Lim, Daniel
    Kattan, Michael W.
    Chakravarti, Arnab
    Gilbert, Mark R.
    Lassman, Andrew B.
    Lo, Simon S.
    Machtay, Mitchell
    Sloan, Andrew E.
    Sulman, Erik P.
    Tian, Devin
    Vogelbaum, Michael A.
    Wang, Tony J. C.
    Penas-Prado, Marta
    Youssef, Emad
    Blumenthal, Deborah T.
    Zhang, Peixin
    Mehta, Minesh P.
    Barnholtz-Sloan, Jill S.
    NEURO-ONCOLOGY, 2017, 19 (05) : 669 - 677
  • [22] Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma
    Jackson, William C.
    Tsien, Christina I.
    Junck, Larry
    Leung, Denise
    Hervey-Jumper, Shawn
    Orringer, Daniel
    Heth, Jason
    Wahl, Daniel R.
    Spratt, Daniel E.
    Cao, Yue
    Lawrence, Theodore S.
    Kim, Michelle M.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 138 (01) : 155 - 162
  • [23] First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
    Liau, Linda M.
    Ashkan, Keyoumars
    Tran, David D.
    Campian, Jian L.
    Trusheim, John E.
    Cobbs, Charles S.
    Heth, Jason A.
    Salacz, Michael
    Taylor, Sarah
    D'andre, Stacy D.
    Iwamoto, Fabio M.
    Dropcho, Edward J.
    Moshel, Yaron A.
    Walter, Kevin A.
    Pillainayagam, Clement P.
    Aiken, Robert
    Chaudhary, Rekha
    Goldlust, Samuel A.
    Bota, Daniela A.
    Duic, Paul
    Grewal, Jai
    Elinzano, Heinrich
    Toms, Steven A.
    Lillehei, Kevin O.
    Mikkelsen, Tom
    Walpert, Tobias
    Abram, Steven R.
    Brenner, Andrew J.
    Brem, Steven
    Ewend, Matthew G.
    Khagi, Simon
    Portnow, Jana
    Kim, Lyndon J.
    Loudon, William G.
    Thompson, Reid C.
    Avigan, David E.
    Fink, Karen L.
    Geofroy, Francois J.
    Lindhorst, Scott
    Lutzky, Jose
    Sloan, Andrew E.
    Schackert, Gabriele
    Krex, Dietmar
    Meisel, Hans-Jorg
    Wu, Julian
    Davis, Raphael P.
    Duma, Christopher
    Etame, Arnold B.
    Mathieu, David
    Kesari, Santosh
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16 : 1
  • [24] A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme
    Rades, Dirk
    Witteler, Jaspar
    Schild, Steven E.
    Trillenberg, Peter
    Bonsanto, Matteo M.
    Leppert, Jan
    ANTICANCER RESEARCH, 2021, 41 (01) : 379 - 384
  • [25] Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection
    Kanamori, Masayuki
    Shibahara, Ichiyo
    Shimoda, Yoshiteru
    Akiyama, Yukinori
    Beppu, Takaaki
    Ohba, Shigeo
    Enomoto, Toshiyuki
    Ono, Takahiro
    Mitobe, Yuta
    Hanihara, Mitsuto
    Mineharu, Yohei
    Ishida, Joji
    Asano, Kenichiro
    Yoshida, Yasuyuki
    Natsumeda, Manabu
    Nomura, Sadahiro
    Abe, Tatsuya
    Yonezawa, Hajime
    Katakura, Ryuichi
    Shibui, Soichiro
    Kuroiwa, Toshihiko
    Suzuki, Hiroyoshi
    Takei, Hidehiro
    Matsushita, Haruo
    Saito, Ryuta
    Arakawa, Yoshiki
    Sonoda, Yukihiko
    Hirose, Yuichi
    Kumabe, Toshihiro
    Yamaguchi, Takuhiro
    Endo, Hidenori
    Tominaga, Teiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (01) : 51 - 61
  • [26] Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients
    Rigamonti, Andrea
    Imbesi, Francesca
    Silvani, Antonio
    Gaviani, Paola
    Agostoni, Elio
    Porcu, Luca
    De Simone, Irene
    Torri, Valter
    Salmaggi, Andrea
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 390 : 14 - 19
  • [27] Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice
    Roux, Alexandre
    Peeters, Sophie
    Zanello, Marc
    Nassif, Rabih Bou
    Lahoud, Georges Abi
    Dezamis, Edouard
    Parraga, Eduardo
    Lechapt-Zalcmann, Emmanuelle
    Dhermain, Frederic
    Dumont, Sarah
    Louvel, Guillaume
    Chretien, Fabrice
    Sauvageon, Xavier
    Devaux, Bertrand
    Oppenheim, Catherine
    Pallud, Johan
    JOURNAL OF NEURO-ONCOLOGY, 2017, 135 (01) : 83 - 92
  • [28] Effect of a Time Delay for Concomitant Chemoradiation After Surgery for Newly Diagnosed Glioblastoma: A Single-Institution Study with Subgroup Analysis According to the Extent of Tumor Resection
    Ahn, Stephen
    Park, Jae-Sung
    Song, Jin Ho
    Jeun, Sin-Soo
    Hong, Yong-Kil
    WORLD NEUROSURGERY, 2020, 133 : E640 - E645
  • [29] Surgical and oncological score to estimate the survival benefit of resection and chemoradiotherapy in elderly (≥70 years) glioblastoma patients: A preliminary analysis
    Zorman, Mark J.
    Webb, Philip
    Nixon, Mickaela
    Sravanam, Sanskrithi
    Honeyman, Susan
    Nandhabalan, Meera
    Apostolopoulos, Vasileios
    Stacey, Richard
    Hobbs, Claire
    Plaha, Puneet
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [30] Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients
    Hui, Caressa Y.
    Rudra, Soumon
    Ma, Sirui
    Campian, Jian L.
    Huang, Jiayi
    JOURNAL OF NEURO-ONCOLOGY, 2019, 143 (01) : 129 - 136